{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:02:02Z","timestamp":1793289722672,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"DOI":"10.1186\/s12959-026-00850-z","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:45:23Z","timestamp":1777045523000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of direct oral anticoagulants in pediatric congenital and acquired heart disease: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"24","author":[{"given":"Hanan El-Sayed","family":"Bakry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai Ibrahim","family":"Abdellah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani Abdelshafook","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Ali","family":"Assem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Mahmoud","family":"ElGamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ibrahim","family":"Abdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Hamouda","family":"Elkasaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3393-9105","authenticated-orcid":false,"given":"Atef A.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"850_CR1","doi-asserted-by":"publisher","unstructured":"Silvey M, Brand\u00e3o LR. Risk Factors, Prophylaxis, and treatment of venous thromboembolism in congenital heart disease patients. Front Pediatr. 2017 Jun;5. https:\/\/doi.org\/10.3389\/fped.2017.00146.","DOI":"10.3389\/fped.2017.00146"},{"key":"850_CR2","doi-asserted-by":"publisher","unstructured":"McCrindle BW, et al. Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)\/National Institutes of Health (NIH) Working Group on thrombosis in pediatric cardiology and congenital heart disease. Circulation. 2014 Sep;130(14):pp. 1192\u20131203. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.008428.","DOI":"10.1161\/CIRCULATIONAHA.113.008428"},{"key":"850_CR3","doi-asserted-by":"publisher","unstructured":"Monagle P, et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv. 2018 Nov;2(22): pp. 3292\u20133316. https:\/\/doi.org\/10.1182\/bloodadvances.2018024786.","DOI":"10.1182\/bloodadvances.2018024786"},{"key":"850_CR4","doi-asserted-by":"publisher","unstructured":"Cohen O, et al. Application of a clinical decision rule and laboratory assays in pediatrics: Adult heparin-induced thrombocytopenia. Pediatr Blood Cancer. 2022 Nov;69(11):e29929. https:\/\/doi.org\/10.1002\/pbc.29929.","DOI":"10.1002\/pbc.29929"},{"key":"850_CR5","doi-asserted-by":"publisher","unstructured":"Bosch A, Albisetti M. Management of venous thromboembolism in children: current recommendations and therapeutic options. TCRM. 2020 Jul;16:673\u20139. https:\/\/doi.org\/10.2147\/TCRM.S218622.","DOI":"10.2147\/TCRM.S218622"},{"key":"850_CR6","doi-asserted-by":"publisher","unstructured":"Lowry AW, Moffett BS, Moodie D, Knudson JD. Warfarin anticoagulation after congenital heart surgery at a large children\u2019s hospital. Pediatr Cardiol. 2012 Dec;33(8):1377\u201382. https:\/\/doi.org\/10.1007\/s00246-012-0351-3.","DOI":"10.1007\/s00246-012-0351-3"},{"key":"850_CR7","doi-asserted-by":"publisher","unstructured":"Roeleveld PP, Van Der Hoeven A, De Wilde RBP, Eikenboom J, Smiers FJ, Bunker-Wiersma HE. Higher tinzaparin dosing is needed to achieve target anti-xa levels in pediatric cardiac intensive care patients. Pediatric Critical Care Medicine. 2016 Mar;17(3): pp. 203\u2013209. https:\/\/doi.org\/10.1097\/PCC.0000000000000640.","DOI":"10.1097\/PCC.0000000000000640"},{"key":"850_CR8","doi-asserted-by":"crossref","unstructured":"Mohamed Taha A, et al. Direct oral anticoagulants versus warfarin for preventing thromboembolic events in valvular heart diseases associated atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials. Circulation. 2023;148, no. Suppl_1, pp. A12514\u2013A12514.","DOI":"10.1161\/circ.148.suppl_1.12514"},{"key":"850_CR9","doi-asserted-by":"publisher","unstructured":"Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Association. 2020 Jul;9(13):e017559. https:\/\/doi.org\/10.1161\/JAHA.120.017559.","DOI":"10.1161\/JAHA.120.017559"},{"key":"850_CR10","doi-asserted-by":"publisher","first-page":"118688","DOI":"10.1016\/j.atherosclerosis.2024.118688","volume":"399","author":"MI Gbreel","year":"2024","unstructured":"Gbreel MI, Balata M, Elkasaby MH, Hassan M, Becher MU. ASAVS. Clopidogrelvs. anticoagulants following mitral valve repair: network-meta-analysis. Atherosclerosis. 2024;399:118688.","journal-title":"Atherosclerosis"},{"key":"850_CR11","doi-asserted-by":"publisher","unstructured":"Gbreel MI, Elkasaby MH, Hassan M, Becher MU, Balata M. Optimizing antithrombotic therapy following mitral valve repair: a comprehensive network meta-analysis. BMC Cardiovasc Disord. 2025 Aug;25(1):628. https:\/\/doi.org\/10.1186\/s12872-025-04974-4.","DOI":"10.1186\/s12872-025-04974-4"},{"key":"850_CR12","doi-asserted-by":"publisher","unstructured":"Wei S, Sawhney A, Khandait H, Meda A, Gupta V, Jain R. An update on applications and limitations of direct oral anticoagulants. Egypt J Intern Med. 2023 Apr;35(1):26. https:\/\/doi.org\/10.1186\/s43162-023-00212-5.","DOI":"10.1186\/s43162-023-00212-5"},{"key":"850_CR13","doi-asserted-by":"publisher","unstructured":"Ageno W, Caramelli B, Donadini MP, Girardi L, Riva N. Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants. Lancet Haematol. 2024 Dec;11(12):e938\u201350. https:\/\/doi.org\/10.1016\/S2352-3026(24)00281-3.","DOI":"10.1016\/S2352-3026(24)00281-3"},{"key":"850_CR14","doi-asserted-by":"publisher","unstructured":"Bosch A, Olivieri M, Holzhauer S. The use of DOACs in pediatrics: current therapeutic and prophylactic indications, cardiac indications, and real-world evidence\u2014a review, hamostaseologie. 2025 Feb;45(01): pp. 089\u2013101. https:\/\/doi.org\/10.1055\/a-2486-6735.","DOI":"10.1055\/a-2486-6735"},{"key":"850_CR15","doi-asserted-by":"publisher","unstructured":"Halton J, et al. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial. Lancet Haematol. 2021 Jan;8(1):e22\u201333. https:\/\/doi.org\/10.1016\/S2352-3026(20)30368-9.","DOI":"10.1016\/S2352-3026(20)30368-9"},{"key":"850_CR16","doi-asserted-by":"publisher","unstructured":"Payne RM, et al. Apixaban for prevention of thromboembolism in pediatric heart disease. J Am Coll Cardiol. 2023 Dec;82(24)pp. 2296\u20132309. https:\/\/doi.org\/10.1016\/j.jacc.2023.10.010.","DOI":"10.1016\/j.jacc.2023.10.010"},{"key":"850_CR17","doi-asserted-by":"publisher","unstructured":"McCrindle BW, et al. Thromboprophylaxis for children post-fontan procedure: insights From the UNIVERSE study. JAHA. 2021 Nov;10:e021765. https:\/\/doi.org\/10.1161\/JAHA.120.021765. no. 22.","DOI":"10.1161\/JAHA.120.021765"},{"key":"850_CR18","doi-asserted-by":"publisher","unstructured":"Portman MA, et al. Edoxaban for thromboembolism prevention in pediatric patients with cardiac disease. J Am Coll Cardiol. 2022 Dec;80(24):pp. 2301\u20132310. https:\/\/doi.org\/10.1016\/j.jacc.2022.09.031.","DOI":"10.1016\/j.jacc.2022.09.031"},{"key":"850_CR19","doi-asserted-by":"publisher","unstructured":"Guan C, Guo L, Liang S. Systematic review of randomized clinical trials on direct oral anticoagulants in pediatric heart diseases. Clin Appl Thromb Hemost. 2024 Jan;30:10760296241271974. https:\/\/doi.org\/10.1177\/10760296241271974.","DOI":"10.1177\/10760296241271974"},{"key":"850_CR20","doi-asserted-by":"publisher","unstructured":"Giossi R, et al. Efficacy and safety of direct oral anticoagulants in the pediatric population: a systematic review and a meta-analysis. J Thromb Haemost. 2023 Oct;21(10):pp. 2784\u20132796. https:\/\/doi.org\/10.1016\/j.jtha.2023.07.011.","DOI":"10.1016\/j.jtha.2023.07.011"},{"key":"850_CR21","doi-asserted-by":"publisher","unstructured":"Higgins JPT, et al. editors. Cochrane handbook for systematic reviews of interventions. 1st ed. Wiley; 2019. https:\/\/doi.org\/10.1002\/9781119536604.","DOI":"10.1002\/9781119536604"},{"key":"850_CR22","doi-asserted-by":"publisher","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group PRISMA. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med. 2009 Jul;6(7):p. e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"850_CR23","doi-asserted-by":"publisher","unstructured":"Higgins JPT, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011 Oct;343:d5928\u20135928. https:\/\/doi.org\/10.1136\/bmj.d5928. oct18 2.","DOI":"10.1136\/bmj.d5928"},{"key":"850_CR24","doi-asserted-by":"publisher","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test, BMJ. 1997 Sep;315(7109): pp. 629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","DOI":"10.1136\/bmj.315.7109.629"},{"key":"850_CR25","doi-asserted-by":"publisher","unstructured":"Albisetti M, et al. Dabigatran for treatment and secondary prevention of venous thromboembolism in pediatric congenital heart disease. JAHA. 2024 Feb;13(4):e028957. https:\/\/doi.org\/10.1161\/JAHA.122.028957.","DOI":"10.1161\/JAHA.122.028957"},{"key":"850_CR26","doi-asserted-by":"publisher","unstructured":"Adkins K, et al. Real-world use and outcomes of apixaban for early post-surgical fontan thromboprophylaxis. Pediatr Cardiol. 2024 Sep. https:\/\/doi.org\/10.1007\/s00246-024-03641-3.","DOI":"10.1007\/s00246-024-03641-3"},{"key":"850_CR27","doi-asserted-by":"publisher","unstructured":"VanderPluym C, et al. Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease. J Thromb Haemost. 2023 Jun;21(6):1601\u20139. https:\/\/doi.org\/10.1016\/j.jtha.2023.03.005.","DOI":"10.1016\/j.jtha.2023.03.005"},{"key":"850_CR28","doi-asserted-by":"publisher","unstructured":"Sagiv E, Newland DM, Slee A, Olson AK, Portman MA. Real-world experience with edoxaban for anticoagulation in children at risk for coronary artery thrombosis, Cardiol Young. 2024 Apr;34(4): pp. 870\u2013875. https:\/\/doi.org\/10.1017\/S1047951123003761.","DOI":"10.1017\/S1047951123003761"},{"key":"850_CR29","doi-asserted-by":"publisher","unstructured":"Chong S, Sun L, Mu G, Hua M, Xiang Q, Cui Y. Adverse events of factor Xa inhibitors in pediatric patients: a meta-analysis and pharmacovigilance study. Pediatr Drugs. 2025 May;27(3):351\u201366. https:\/\/doi.org\/10.1007\/s40272-024-00665-3.","DOI":"10.1007\/s40272-024-00665-3"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-026-00850-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00850-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00850-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:50:22Z","timestamp":1777366222000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12959-026-00850-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["850"],"URL":"https:\/\/doi.org\/10.1186\/s12959-026-00850-z","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}